FP10'un PB Oranı emsallerine kıyasla nasıldır?

FP10, Price-To-Book değerine göre iyi bir değerdir. Eş ortalamaya (0.9x) kıyasla oran (15.2x).

FP10'nin PB Oranı, DE Biotechs Sektöründeki diğer şirketlerle karşılaştırıldığında nasıldır?

FP10 Price-To-Book Oranı ( 0.9 x) baz alındığında, German Biotechs sektör ortalamasına ( 2 x) kıyasla iyi bir değerdir.

FP10'nin PB Oranı, Adil PB Oranına kıyasla nedir? Bu, şirketin tahmini kazanç büyümesini, kar marjlarını ve diğer risk faktörlerini dikkate alan beklenen PB Oranıdır.

Değerleme analizi için FP10 'in Price-To-Book Adil Oranını hesaplamak için yeterli veri yok.

Gelecekteki nakit akışlarına bakıldığında FP10 'un Adil Fiyatı nedir? Bu tahmin için İndirgenmiş Nakit Akışı modelini kullanıyoruz.

FP10 'un değerleme analizi için adil değerinin hesaplanmasında yeterli veri bulunmamaktadır.

Analistin 12 aylık tahmini nedir ve konsensüs fiyat hedefine istatistiksel olarak güveniyor muyuz?

Fiyat tahminini göstermek için yeterli veri yok.

Salarius Pharmaceuticals (DB:FP10) - Hisse Senedi Fiyatı, Haberler ve Analizler

FP10 Stoklara Genel Bakış

A clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Daha fazla detay

FP10 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Hisse senetleri oldukça likit değildir

Anlamlı bir piyasa değeri yok ( €2M )

1 yıldan az nakit akışı var

+ 3 daha fazla risk

Salarius Pharmaceuticals, Inc. Rakipler

bioXXmed

XTRA:T5O

€1.4m

4SC

DB:VSC

€48.2m

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€22.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Salarius Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$3.01
52 Haftanın En Yüksek Seviyesi	US$6.40
52 Haftanın En Düşük Seviyesi	US$2.74
Beta	0.96
11 Aylık Değişim	0%
3 Aylık Değişim	0%
1 Yıllık Değişim	-48.49%
33 Yıllık Değişim	-98.23%
5 Yıllık Değişim	-99.75%
Halka arzdan bu yana değişim	-99.88%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	FP10	DE Biotechs	DE Pazar
7D	0%	-0.7%	-0.02%
1Y	-48.5%	-17.2%	8.2%

Getiri vs. Endüstri: FP10 geçen yıl % -17.2 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: FP10 geçen yıl % 8.2 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is FP10's price volatile compared to industry and market?
FP10 volatility
FP10 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

İstikrarlı Hisse Senedi Fiyatı: FP10 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: FP10 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	2	David Arthur	www.salariuspharma.com

Salarius Pharmaceuticals, Inc. Temel Bilgiler Özeti

Salarius Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
FP10 temel i̇stati̇sti̇kler
Piyasa değeri	€1.97m
Kazançlar(TTM)	-€5.86m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.3x

F/K Oranı

FP10 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
FP10 gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$6.46m
Kazançlar	-US$6.46m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-4.49
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

FP10 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

FP10 Stoklara Genel Bakış

Risk Analizi

Salarius Pharmaceuticals, Inc. Rakipler

XTRA:T5O

€1.4m

DB:VSC

€48.2m

XTRA:CNW

€6.5m

XTRA:MDG1

€22.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Salarius Pharmaceuticals, Inc., Annual General Meeting, Dec 20, 2024

Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with Mds and Cmml Presented At the 2024 European Hematology Association Annual Meeting

New major risk - Shareholder dilution

Nasdaq Grants an Additional 180-Day Grace Period to Salarius Pharmaceuticals to Regain Compliance

Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Recent updates

Salarius Pharmaceuticals, Inc., Annual General Meeting, Dec 20, 2024

Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with Mds and Cmml Presented At the 2024 European Hematology Association Annual Meeting

New major risk - Shareholder dilution

Nasdaq Grants an Additional 180-Day Grace Period to Salarius Pharmaceuticals to Regain Compliance

Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals Receives Notice from Nasdaq Stock Market

Insufficient new directors

Salarius Pharmaceuticals, Inc. FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Salarius Pharmaceuticals, Inc. announced that it has received $6.000001 million in funding

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Pharmaceuticals Presents Sp-3164 Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. to Present SP-3164 Targeted Protein Degrader Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. Announces Investigators Present Clinical Data on Its Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. Reports Impairment of Goodwill for the Three Months Ended September 30, 2022

Salarius Pharmaceuticals Presents Favorable Preclinical Data on Sp-3164 At the 5Th Annual Targeted Protein Degradation Conference

Salarius Pharmaceuticals, Inc. Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for Ongoing Trial of Seclidemstat as A Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

Salarius Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Salarius Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

Salarius Pharmaceuticals, Inc. (NasdaqCM:SLRX) acquired certain assets of DeuteRx, including DRX-164 for approximately $220 million.

Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial

Second quarter 2021 earnings released: US$0.069 loss per share (vs US$0.13 loss in 2Q 2020)

Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers

Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’S Safety, Dosing, and Drug Activity At American Society of Clinical Oncology (Asco) 2021 Annual Meeting

Salarius Pharmaceuticals, Inc. Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

First quarter 2021 earnings released: US$0.061 loss per share (vs US$0.22 loss in 1Q 2020)

Full year 2020 earnings released: US$0.50 loss per share (vs US$2.12 loss in FY 2019)

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Salarius Pharmaceuticals, Inc. Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas

Salarius Pharmaceuticals, Inc. Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients

New 90-day high: €1.16

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Salarius Pharmaceuticals, Inc. Announces Developing Seclidemstat

New 90-day high: €1.05

New 90-day high: €0.88

Third quarter 2020 earnings released: US$0.096 loss per share

Revenue beats expectations

New 90-day low: €0.66

New 90-day low: €0.67

New 90-day low - €0.79

New 90-day low - €0.83

Earnings released

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.353451 million.